|
BARD1 Changes its Name to INOVIQ
|
8 December 2021 at 9:20am
|
|
Cleansing Notice - Issued of Four Shares - Resolution 5 AGM
|
7 December 2021 at 12:40pm
|
|
Application for quotation of securities - BD1
|
7 December 2021 at 12:30pm
|
|
Application for quotation of securities - BD1
|
2 December 2021 at 3:05pm
|
|
Results of 2021 Annual General Meeting
|
30 November 2021 at 8:50am
|
|
AGM Presentation
|
29 November 2021 at 2:20pm
|
|
New BARD1 Exosome Liquid Biopsy Project
|
29 November 2021 at 10:55am
|
|
Application for quotation of securities - BD1
|
25 November 2021 at 3:55pm
|
|
Notification regarding unquoted securities - BD1
|
22 November 2021 at 3:35pm
|
|
US Patent Issued - BARD1 Patent Family Lung Cancer Diagnosis
|
12 November 2021 at 10:10am
|
|
EXO-NET ANZSEV Presentation
|
10 November 2021 at 1:35pm
|
|
BARD1 Presenting at Bell Potter Healthcare Conference
|
10 November 2021 at 12:20pm
|
|
EXO-NET Presented at Virtual ANZSEV Symposium
|
10 November 2021 at 10:05am
|
|
Jobkeeper Payment Notification
|
9 November 2021 at 4:10pm
|
|
Notice of Annual General Meeting/Proxy Form
|
1 November 2021 at 10:10am
|
|
Ceasing to be a substantial holder
|
29 October 2021 at 6:10pm
|
|
Appendix 4G and Corporate Governance Statement
|
29 October 2021 at 3:15pm
|
|
Appendix 4C & Quarterly Activities Report
|
29 October 2021 at 10:45am
|
|
Change of Director's Interest - Philip Powell
|
22 October 2021 at 9:15am
|
|
Amended Remuneration Table Directors Report
|
20 October 2021 at 4:59pm
|
|
Notice required under listing rule 3.13.1
|
11 October 2021 at 5:50pm
|
|
Notification of cessation of securities - BD1
|
1 October 2021 at 11:15am
|
|
2021 Annual Report
|
29 September 2021 at 9:50am
|
|
BARD1 Appoints New CSO
|
16 September 2021 at 10:20am
|
|
Notification of cessation of securities - BD1
|
7 September 2021 at 2:40pm
|
|
Appendix 4E and Preliminary Financial Report
|
31 August 2021 at 2:30pm
|
|
Change in substantial holding
|
27 August 2021 at 6:00pm
|
|
Change of Director's Interest - Powell
|
27 August 2021 at 2:55pm
|
|
Change of Director's Interest - Dr Geoffrey Cumming
|
27 August 2021 at 2:55pm
|
|
Change of Director's Interest - Johnston
|
27 August 2021 at 2:50pm
|
|
Notification of cessation of securities - BD1
|
24 August 2021 at 3:40pm
|
|
Appendix 2A
|
24 August 2021 at 10:40am
|
|
BARD1 Share Purchase Plan Completed Oversubscribed
|
23 August 2021 at 9:25am
|
|
Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test
|
17 August 2021 at 9:00am
|
|
BARD1 LODGES SPP AND OPTIONS PROSPECTUS
|
30 July 2021 at 10:40am
|
|
Appendix 4C & Quarterly Activities Report
|
30 July 2021 at 9:00am
|
|
Appendix 2A
|
29 July 2021 at 11:55am
|
|
BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data
|
28 July 2021 at 10:25am
|
|
Updated Investor Presentation
|
23 July 2021 at 12:50pm
|
|
Terms of issue of Options
|
23 July 2021 at 12:45pm
|
|
Investor Presentation
|
23 July 2021 at 12:10pm
|
|
Appendix 3B
|
23 July 2021 at 12:05pm
|
|
BARD1 $15m Placement to Accelerate Cancer Diagnostic Program
|
23 July 2021 at 12:05pm
|
|
Trading Halt
|
21 July 2021 at 8:50am
|
|
BARD1 Investor Presentation
|
7 July 2021 at 10:10am
|
|
BARD1 Autoantibody Test Results for Ovarian Cancer Published
|
29 June 2021 at 8:45am
|
|
SubB2M Breast Cancer Test Manuscript Submitted
|
25 June 2021 at 8:45am
|
|
Update on Legal Proceedings
|
4 June 2021 at 10:45am
|
|
R&D Tax Incentive Refund Received
|
31 May 2021 at 11:20am
|
|
BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test
|
25 May 2021 at 9:55am
|
BARD1 Life Sciences